Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that despite negative impact of the Women's Health Initiative (WHI) and the Heart and Estrogen/Progestin Replacement Study (HERS II), the hormone replacement therapy (HRT) drug market will experience robust growth. According to the new Pharmacor study entitled Hormone Replacement Therapy, one such drug that will take advantage of patients' and physicians' concerns with traditional HRT products is Eli Lilly's Evista. Evista is currently the only selective estrogen receptor modulator (SERM) approved for the prevention and treatment of postmenopausal osteoporosis.
"Although some women who discontinued HRT immediately following the WHI and HERS II announcements have since resumed their HRT regimens, many thought leaders believe that these two studies irreparably damaged physician and patient confidence in the safety of HRT agents. As a result, it is unlikely the percentage of drug-treated women will reach the levels seen before the WHI and HERS II results were published," said Carilee Berg, Ph.D., analyst at Decision Resources. "However, the most exciting area of development in the HRT market involves SERMs, like Lilly's Evista."
Background -- The HRT Dilemma
In the summer of 2002, results from WHI and HERS II were announced. They cited an increased risk for breast cancer, cardiovascular disease, stroke, and venous thromboembolism associated with the long-term use of Wyeth's Prempro, and caused widespread concern. These findings significantly affected HRT market in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) -- particularly in the United States, where Prempro is highly popular. Immediately following the WHI and HERS II announcements, there was a steep decline in the number of women treated with HRT, as well as shifts in patient share among key HRT drug classes and formulations.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Hormone Replacement Therapy is a Mosaic report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.,
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/